Skip to main content

Table 2 Summary of treatment effects: 1860 and LEAD-6 trials & long-term progression approach

From: Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

Risk Factor 1860 clinical trial* LEAD-6 clinical trial Long-term progression
  Liraglutide (1.2 mg) Sitagliptin (100 mg) Liraglutide (1.8 mg) Exenatide BID (10 μg) All comparators
  Mean SD Mean SD Mean SD Mean SD  
Change from baseline in HbA1c (%) −1.24 1.04 −0.90 1.04 −1.12 1.22 −0.79 1.22 No HbA1c creep assumption
Change from baseline in SBP (mm Hg) −0.55 13.23 −0.94 13.17 −2.51 17.55 −2.00 17.93 UKPDS progression
Change from baseline in total cholesterol (mmol/l) −0.03 0.82 −0.02 0.80 −0.20 1.02 −0.09 1.01 Framingham progression
Change from baseline in LDL (mmol/l) 0.08 0.69 0.13 0.68 −0.44 0.84 −0.40 0.84 Framingham progression
Change from baseline in HDL (mmol/l) 0.00 0.17 0.00 0.17 −0.04 0.23 −0.05 0.23 Framingham progression
Change from baseline in triglycerides (mmol/l) −0.19 1.42 −0.40 1.38 −0.41 1.50 −0.23 1.48 Framingham progression
Change from baseline in BMI (kg/m2) −1.00 0.08 −0.34 0.08 −1.15 1.35 −1.02 1.47 Constant after returning to baseline
Major hypoglycaemia (events per 100 patient-years) 1.00   0.00   0.00   2.00   0.00#
Minor hypoglycaemia (events per 100 patient-years) 17.80   10.60   193.20   260.00   128.70#
  1. *P between treatment arms < 0.001 for change in HbA1c and BMI. P between treatment arms < 0.0001 for change in HbA1c and P < 0.05 for change in triglycerides and minor hypoglycaemic events. #Long-term hypoglycaemic event rates were based on the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) study [14]. HbA1c = glycated haemoglobin; BMI = body mass index; LDL = low-density lipoprotein; HDL = high density lipoprotein; SBP = Systolic blood pressure; UKPDS = United Kingdom Prospective Diabetes Study; SD = standard deviation.